DE60023043T2 - (S,S)-Reboxetin zur Behandlung von Inkontinenz - Google Patents

(S,S)-Reboxetin zur Behandlung von Inkontinenz Download PDF

Info

Publication number
DE60023043T2
DE60023043T2 DE60023043T DE60023043T DE60023043T2 DE 60023043 T2 DE60023043 T2 DE 60023043T2 DE 60023043 T DE60023043 T DE 60023043T DE 60023043 T DE60023043 T DE 60023043T DE 60023043 T2 DE60023043 T2 DE 60023043T2
Authority
DE
Germany
Prior art keywords
reboxetine
incontinence
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023043T
Other languages
German (de)
English (en)
Other versions
DE60023043D1 (de
Inventor
Saeeduddin Ahmed
Lars Birgerson
Pasquale Cetera
Robert Clyde Marshall
Robert Mcarthur
Duncan P Taylor
Erik H F Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60023043(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Application granted granted Critical
Publication of DE60023043D1 publication Critical patent/DE60023043D1/de
Publication of DE60023043T2 publication Critical patent/DE60023043T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60023043T 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz Expired - Lifetime DE60023043T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13

Publications (2)

Publication Number Publication Date
DE60023043D1 DE60023043D1 (de) 2006-02-16
DE60023043T2 true DE60023043T2 (de) 2006-06-14

Family

ID=27495506

Family Applications (9)

Application Number Title Priority Date Filing Date
DE60023043T Expired - Lifetime DE60023043T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE60019473T Expired - Lifetime DE60019473T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60026704T Expired - Lifetime DE60026704T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60020613T Expired - Lifetime DE60020613T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen

Family Applications After (8)

Application Number Title Priority Date Filing Date
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE60019473T Expired - Lifetime DE60019473T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60026704T Expired - Lifetime DE60026704T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60020613T Expired - Lifetime DE60020613T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen

Country Status (30)

Country Link
US (18) US6465458B1 (enExample)
EP (3) EP2090312A1 (enExample)
JP (3) JP2003503450A (enExample)
KR (5) KR100935277B1 (enExample)
CN (5) CN1289090C (enExample)
AR (1) AR035158A1 (enExample)
AT (9) ATE364386T1 (enExample)
AU (2) AU771258B2 (enExample)
BR (1) BR0012136A (enExample)
CA (2) CA2375908C (enExample)
CL (3) CL2008002867A1 (enExample)
CO (1) CO5190662A1 (enExample)
CZ (1) CZ299847B6 (enExample)
DE (9) DE60023043T2 (enExample)
DK (4) DK1459749T3 (enExample)
EA (6) EA005029B1 (enExample)
ES (9) ES2285645T3 (enExample)
GE (1) GEP20094798B (enExample)
HU (1) HUP0201623A3 (enExample)
IL (3) IL147246A0 (enExample)
MX (1) MXPA02000562A (enExample)
MY (1) MY137348A (enExample)
NO (4) NO20016406L (enExample)
NZ (2) NZ533243A (enExample)
PE (1) PE20010684A1 (enExample)
PL (1) PL196996B1 (enExample)
PT (5) PT1459750E (enExample)
SK (5) SK286667B6 (enExample)
TW (9) TWI298254B (enExample)
WO (1) WO2001001973A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364386T1 (de) * 1999-07-01 2007-07-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
TWI238062B (en) * 1999-12-01 2005-08-21 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
AU2001255223B2 (en) * 2000-04-21 2004-10-21 Pharmacia And Upjohn Company Llc Treatment of fibromyalgia and chronic fatigue syndrome
EP1274430B1 (en) * 2000-04-21 2005-12-14 Pharmacia & Upjohn Company LLC Cabergoline for the treatment of fibromyalgia and chronic fatigue syndrome
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE60234873D1 (de) * 2001-06-19 2010-02-04 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
ES2295435T3 (es) * 2001-12-11 2008-04-16 Eli Lilly And Company Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo.
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1482921A1 (en) * 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
AU2003225206B2 (en) * 2002-04-24 2008-02-14 Forest Laboratories Holdings Limited Prevention and treatment of functional somatic disorders, including stress-related disorders
KR20110043664A (ko) * 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
EP1513529B1 (en) * 2002-05-30 2011-12-14 NeuroSearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
WO2003106441A1 (en) * 2002-06-17 2003-12-24 Pharmacia Italia S.P.A. Pharmaceutical salts of reboxetine
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
NZ537521A (en) * 2002-08-14 2007-05-31 Pharmacia & Upjohn Co Llc Use of reboxetine for the treatment of hot flashes
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ES2264028T3 (es) 2002-08-23 2006-12-16 Eli Lilly And Company Derivados de bencilmorfolina.
CA2500662A1 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
PL378369A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
ATE365554T1 (de) * 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
NZ545494A (en) * 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1729754B1 (en) * 2003-12-12 2008-07-02 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
WO2005066144A1 (en) * 2003-12-23 2005-07-21 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
GEP20084550B (en) * 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
RU2006143659A (ru) * 2004-06-09 2008-06-20 Пфайзер Инк. (Uпфайзер Инк. (Us)S) Применение ребоксетина для лечения боли
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
UA89052C2 (ru) 2004-08-13 2009-12-25 Бёрингер Ингельхайм Интернациональ Гмбх Композиция таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применения
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080015181A1 (en) * 2006-06-28 2008-01-17 Chelsea Therapeutics, Inc. Pharmaceutical Compositions Comprising Droxidopa
KR20160072276A (ko) 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
BRPI0808647A2 (pt) 2007-03-09 2014-08-12 Chelsea Therapeutics Inc Método para tratar a síndrome de sensibilidade central, método para reduzir, eliminar ou prevenir a dor associada à fibromialgia, kit útil para o tratamento de uma síndrome de sensibilidade central.
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008134325A1 (en) * 2007-04-30 2008-11-06 Adolor Corporation Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
NZ581707A (en) * 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
JP2012524098A (ja) * 2009-04-15 2012-10-11 セラヴァンス， インコーポレーテッド ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
NZ597433A (en) * 2009-07-13 2013-12-20 Theravance Inc 3-phenoxymethylpyrrolidine compounds
WO2011011231A1 (en) * 2009-07-21 2011-01-27 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
CN103153950B (zh) 2010-10-11 2015-11-25 施万生物制药研发Ip有限责任公司 血清素再摄取抑制剂
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
ES3037824T3 (en) 2012-06-06 2025-10-07 Nalpropion Pharmaceuticals Llc Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
AU2020395082A1 (en) * 2019-12-03 2022-06-09 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ZA921292B (en) 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0921802A4 (en) 1996-03-25 2002-05-08 Lilly Co Eli METHODS FOR TREATING PAIN
JP2000507544A (ja) 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
ATE172117T1 (de) 1996-11-27 1998-10-15 Pfleger R Chem Fab Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
EP1007041A4 (en) 1997-04-11 2001-03-07 Lilly Co Eli COMPOSITION FOR TREATING PAIN
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
CA2306233A1 (en) 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ATE301462T1 (de) * 1998-04-09 2005-08-15 Pharmacia & Upjohn Co Llc Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
PL345351A1 (en) * 1998-05-08 2001-12-17 Upjohn Co New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
KR20010078754A (ko) 1998-06-29 2001-08-21 추후제출 통증 경감 방법 및 통증 경감용 경피 조성물
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
ATE364386T1 (de) 1999-07-01 2007-07-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
ATE305788T1 (de) 2005-10-15
EA200400589A1 (ru) 2004-12-30
EA200801805A1 (ru) 2008-12-30
DE60019473T2 (de) 2006-02-23
TW200407146A (en) 2004-05-16
NO20016406L (no) 2002-02-19
JP2006321815A (ja) 2006-11-30
IL187512A0 (en) 2008-06-05
DE60022692T2 (de) 2006-06-22
US6610690B2 (en) 2003-08-26
EP2087892A2 (en) 2009-08-12
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (en) 2002-04-17
ATE320257T1 (de) 2006-04-15
AU2004202096A1 (en) 2004-06-10
EA008381B1 (ru) 2007-04-27
US7723334B2 (en) 2010-05-25
EA200200111A1 (ru) 2002-06-27
ES2258251T3 (es) 2006-08-16
WO2001001973A3 (en) 2002-01-17
HK1076723A1 (en) 2006-01-27
DK1459750T3 (da) 2005-08-15
CL2008002867A1 (es) 2009-01-09
KR20050053799A (ko) 2005-06-08
DE60026704T2 (de) 2006-10-19
EP1196172B1 (en) 2006-03-15
US20060135521A1 (en) 2006-06-22
PT1632234E (pt) 2007-07-09
CN1660108A (zh) 2005-08-31
ATE292971T1 (de) 2005-04-15
DE60022917D1 (de) 2006-02-09
EA011094B1 (ru) 2008-12-30
DE60035232D1 (de) 2007-07-26
BR0012136A (pt) 2002-06-11
TW200607512A (en) 2006-03-01
TWI245631B (en) 2005-12-21
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
CA2643231A1 (en) 2001-01-11
US6465458B1 (en) 2002-10-15
SK286668B6 (sk) 2009-03-05
US7338953B2 (en) 2008-03-04
CZ20014625A3 (cs) 2002-08-14
TW200920378A (en) 2009-05-16
CL2008002866A1 (es) 2009-01-09
WO2001001973A2 (en) 2001-01-11
AU2004202096B2 (en) 2005-10-20
EA200501496A1 (ru) 2006-06-30
AR035158A1 (es) 2004-05-05
US20060128705A1 (en) 2006-06-15
NZ515885A (en) 2004-08-27
PT1196172E (pt) 2006-05-31
CA2375908C (en) 2006-05-30
KR100704319B1 (ko) 2007-04-09
IL187513A0 (en) 2008-06-05
CN1660111A (zh) 2005-08-31
US6642235B2 (en) 2003-11-04
DE60020613T2 (de) 2006-03-16
NO20016406D0 (no) 2001-12-28
AU771258B2 (en) 2004-03-18
AU5633700A (en) 2001-01-22
US20090247528A1 (en) 2009-10-01
US20080103145A1 (en) 2008-05-01
DE60022917T2 (de) 2006-06-29
SK286104B6 (sk) 2008-03-05
DE60026627T2 (de) 2007-02-01
TW200607510A (en) 2006-03-01
KR20060099544A (ko) 2006-09-19
US20060264436A1 (en) 2006-11-23
US20020128173A1 (en) 2002-09-12
ES2247572T3 (es) 2006-03-01
SK19382001A3 (sk) 2002-07-02
US7317011B2 (en) 2008-01-08
HUP0201623A3 (en) 2004-12-28
TWI298254B (en) 2008-07-01
KR100717660B1 (ko) 2007-05-15
GEP20094798B (en) 2009-10-26
DE60035232T2 (de) 2008-02-14
MY137348A (en) 2009-01-30
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
PT1459751E (pt) 2005-11-30
DE60020613D1 (de) 2005-07-07
KR20020015363A (ko) 2002-02-27
PE20010684A1 (es) 2001-06-24
HK1049630A1 (en) 2003-05-23
TW200914027A (en) 2009-04-01
DE60022692D1 (de) 2005-10-20
EA200801806A1 (ru) 2008-12-30
US7276503B2 (en) 2007-10-02
US7241762B2 (en) 2007-07-10
CL2008002868A1 (es) 2009-01-09
US20080103147A1 (en) 2008-05-01
HUP0201623A2 (en) 2002-09-28
WO2001001973A8 (en) 2001-05-17
ES2246485T3 (es) 2006-02-16
TW200607511A (en) 2006-03-01
EA005029B1 (ru) 2004-10-28
ES2285645T3 (es) 2007-11-16
US6987107B2 (en) 2006-01-17
US6703389B2 (en) 2004-03-09
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
ATE296634T1 (de) 2005-06-15
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
PL352252A1 (en) 2003-08-11
TWI294779B (en) 2008-03-21
CN1660110A (zh) 2005-08-31
JP2006143749A (ja) 2006-06-08
US20080103146A1 (en) 2008-05-01
SK286864B6 (sk) 2009-06-05
DK1632234T3 (da) 2007-09-17
US20030040464A1 (en) 2003-02-27
DE60022916D1 (de) 2006-02-09
DE60026704D1 (de) 2006-05-11
US20020061910A1 (en) 2002-05-23
DE60022916T2 (de) 2006-07-06
CN1205935C (zh) 2005-06-15
CN1289090C (zh) 2006-12-13
ATE304358T1 (de) 2005-09-15
EP2090312A1 (en) 2009-08-19
US20060135520A1 (en) 2006-06-22
JP2003503450A (ja) 2003-01-28
NO20091158L (no) 2002-02-19
TWI298255B (en) 2008-07-01
KR100935277B1 (ko) 2010-01-06
KR100948757B1 (ko) 2010-03-23
ES2246487T3 (es) 2006-02-16
TW200607509A (en) 2006-03-01
CN1660109A (zh) 2005-08-31
ATE305307T1 (de) 2005-10-15
NO20091168L (no) 2002-02-19
TWI293250B (en) 2008-02-11
US20020107249A1 (en) 2002-08-08
ES2258010T3 (es) 2006-08-16
CZ299847B6 (cs) 2008-12-10
PL196996B1 (pl) 2008-02-29
ATE319453T1 (de) 2006-03-15
EP2087892A3 (en) 2009-09-30
EA006652B1 (ru) 2006-02-24
NZ533243A (en) 2005-12-23
KR20090087134A (ko) 2009-08-14
ES2246488T3 (es) 2006-02-16
PT1459750E (pt) 2005-08-31
CA2375908A1 (en) 2001-01-11
ES2242175T3 (es) 2005-11-01
DE60019473D1 (de) 2005-05-19
SK286669B6 (sk) 2009-03-05
MXPA02000562A (es) 2002-07-02
ATE305306T1 (de) 2005-10-15
US20040147614A1 (en) 2004-07-29
US20080096890A1 (en) 2008-04-24
US20060142289A1 (en) 2006-06-29
ES2239311T3 (es) 2005-09-16
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
SK286667B6 (sk) 2009-03-05
KR20090087135A (ko) 2009-08-14
CN1379672A (zh) 2002-11-13
DK1459749T3 (da) 2006-01-09
NO20091159L (no) 2002-02-19

Similar Documents

Publication Publication Date Title
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60039415D1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60138129D1 (de) Apparat zur behandlung von zähnen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60022826D1 (de) Absorbierender Wegwerfartikel zur Behandlung von Fäkalien
ATE298569T1 (de) Virus behandlung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
DE60011060D1 (de) Virus behandlung
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
DK1459748T3 (da) (S,S)-reboxetin til behandling af perifer neuropati
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
EP1244467A4 (en) PHOSPHOGLYCERATE KINASE IN THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition